HHC Medical

HHC Medical, based in Denmark, specializes in the development of innovative technology for targeted and non-invasive drug delivery, enhancing therapeutic applications while prioritizing patient comfort. HHC Medical is focused on creating advanced solutions for drug delivery through wireless electroporation technology. Founded in Copenhagen S, Denmark, the company has undergone no notable pivots in strategy and does not operate as a subsidiary nor is it a parent to other companies. The founder's background is not specified.

In December 2025, HHC Medical raised EUR 165,000 in pre-seed funding from investor Antler, marking the only known deal to date, with a total amount raised of EUR 165,000. HHC Medical specializes in a revolutionary platform technology that enables targeted and non-invasive drug delivery through wireless electroporation. This innovative method leverages an established biophysical phenomenon to facilitate the delivery of diverse therapeutic payloads, enhancing safety and efficacy while minimizing discomfort for patients. The core product offering addresses various medical use cases, particularly in oncology and chronic disease management, where traditional delivery methods may fall short.

The company serves a wide range of healthcare providers, including hospitals, specialized clinics, and research institutions across Europe and North America, with aspirations to expand into additional markets as the technology matures. The proprietary technology has been in development for several years, focusing on refining its applications for clinical settings. HHC Medical generates revenue primarily through partnerships with healthcare facilities and direct sales to medical institutions. Transactions typically involve licensing their electroporation technology to hospitals and clinics, which may enter agreements for access to the platform, alongside training and support services.

The pricing structure includes one-time fees for equipment and recurring service fees for maintenance and updates, reflecting the ongoing support accompanying the technology deployment. Flagship products include their wireless electroporation system, offered as a comprehensive package that includes educational materials and user support. The revenue model is designed to foster long-term relationships with clients, ensuring consistent performance and satisfaction with their solutions. HHC Medical plans to utilize the recent funding of EUR 165,000 raised in December 2025 to enhance their product offerings and expand their market presence.

The company is focusing on developing new products aimed at improving non-invasive drug delivery technologies, with specific timelines for launches yet to be detailed. Additionally, there are targeted efforts to expand into new markets across Europe and North America, aligning with their strategy to reach more healthcare providers as their technology matures.